Clinical Trial Detail

NCT ID NCT02163694
Title A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors AbbVie
Indications

Her2-receptor negative breast cancer

Therapies

Carboplatin + Paclitaxel + Veliparib

Carboplatin + Paclitaxel

Age Groups: adult senior

Additional content available in CKB BOOST